Volunteer s Death Unrelated To Covaxin: Bharat Biotech We cannot confirm if the volunteer received the study vaccine or a placebo as the study is blinded, the vaccine major noted. PTI outlookindia.com 2021-01-09T20:56:07+05:30
After the death of a 42-year-old volunteer in Bhopal, who took a dose of Covaxin in the clinical trial of Bharat Biotech s Covaxin, further spurred controversy over the emergency approval of the firm s covid vaccine, Bharat Biotech denied that the vaccine was the cause of the volunteer s death.
Vaccine maker Bharat Biotech on Saturday said the death of a volunteer in Bhopal, who took a shot of its COVID-19 vaccine Covaxin as part of the Phase III clinical trials, was not related to the medication.
Volunteer s death in Bhopal not related to vaccine, may be of poisoning: Bharat Biotech
India
Published: Saturday, January 9, 2021, 20:43 [IST]
New Delhi, Jan 09: Vaccine maker Bharat Biotech on Saturday said the death of a volunteer in Bhopal, who took a shot of its COVID-19 vaccine Covaxin as part of the Phase III clinical trials, was not related to the medication.
Representational Image As per the post-mortem report issued by the Gandhi Medical College, Bhopal that the site received from the Bhopal Police, the probable cause of death was due to cardio respiratory failure as a result of suspected poisoning and the case is under police investigation as well, the Hyderabad-based firm said in a statement.
Zydus to initiate Ph III trials of COVID-19 vaccine candidate
Zydus to initiate Ph III trials of COVID-19 vaccine candidate
01 January 2021 | News The Phase II study of the vaccine ZyCoV-D had been conducted in over 1000 healthy adult volunteers
Source credit: Shutterstock
Zydus Cadila has announced that its plasmid DNA vaccine to prevent COVID-19, ZyCoV-D was found to be safe, well tolerated and immunogenic in the Phase I/II clinical trials. The company is now planning to initiate Phase III clinical trial in around 30,000 volunteers upon receiving necessary approvals.
The Phase II study of the vaccine ZyCoV-D had been conducted in over 1000 healthy adult volunteers as part of the adaptive Phase I/II dose escalation, multi-centric, randomised, double-blind placebo controlled study. The vaccine was found to be safe and immunogenic.
Data from the COVE study, which evaluated mRNA-1273, a vaccine candidate against COVID-19 manufactured by Moderna, Inc., demonstrated 94.1 percent efficacy in preventing symptomatic COVID-19.